{
  "kind": "treatment",
  "slug": "varenicline-chantix",
  "type": "medication",
  "name": "Varenicline",
  "summary": "Varenicline is a smoking cessation aid that reduces cravings and withdrawal symptoms by partially stimulating nicotine receptors.",
  "description": "Varenicline, marketed under the brand name Chantix, is a partial agonist at the alpha4beta2 nicotinic acetylcholine receptor. It reduces cravings and withdrawal symptoms associated with smoking cessation while also decreasing the rewarding effects of nicotine from cigarettes. It is prescribed as part of a comprehensive smoking cessation program including behavioral support.",
  "category": "medications/addiction",
  "tags": [
    "smoking cessation",
    "nicotine addiction",
    "partial agonist",
    "tobacco use disorder"
  ],
  "metadata": {
    "drug_classes": [
      "Smoking cessation aid",
      "Partial nicotinic receptor agonist"
    ],
    "therapeutic_categories": [
      "Addiction medicine",
      "Preventive care"
    ],
    "mechanism_categories": [
      "Alpha Blocker"
    ],
    "administration_routes": [
      "Oral"
    ],
    "prescription_status": "Prescription only",
    "controlled_substance": false,
    "generic_available": true,
    "brand_names": [
      "Chantix"
    ],
    "age_groups": [
      "Adult"
    ],
    "treatment_duration": [
      "Short-term (12–24 weeks)"
    ],
    "specialty_areas": [
      "Addiction medicine",
      "Primary care"
    ],
    "fda_approval_year": 2006
  },
  "clinical_metadata": {
    "primary_indications": [
      "Other"
    ],
    "off_label_uses": [
      "Smokeless tobacco cessation",
      "E-cigarette/vaping cessation"
    ],
    "contraindications": [
      "History of serious hypersensitivity reactions to varenicline or formulation components"
    ],
    "monitoring_required": [
      "Mood and behavioral changes",
      "Neuropsychiatric symptoms",
      "Renal function in patients with impairment"
    ],
    "efficacy_rating": {
      "Smoking cessation": 3
    }
  },
  "search_metadata": {
    "searchable_terms": [
      "varenicline",
      "Chantix",
      "smoking cessation aid"
    ],
    "synonyms": [
      "Chantix",
      "varenicline tartrate"
    ],
    "common_misspellings": [
      "vareniclene",
      "varnacline",
      "varanacline"
    ]
  },
  "sections": [
    {
      "type": "indications",
      "items": [
        "Smoking cessation aid in adults"
      ]
    },
    {
      "type": "mechanism",
      "text": "Partial agonist at alpha4beta2 nicotinic acetylcholine receptors, reducing cravings and withdrawal symptoms while attenuating the reinforcing effects of nicotine."
    },
    {
      "type": "dosing",
      "adult": {
        "oral": "Days 1–3: 0.5 mg once daily; Days 4–7: 0.5 mg twice daily; Day 8 onward: 1 mg twice daily for a total of 12 weeks. May extend an additional 12 weeks to reduce relapse."
      },
      "pediatric": {
        "oral": "Safety and efficacy not established in individuals under 18 years."
      }
    },
    {
      "type": "dosage_forms",
      "items": [
        "Tablets: 0.5 mg, 1 mg"
      ]
    },
    {
      "type": "onset_duration",
      "text": "Craving reduction and diminished reward from smoking may begin within the first week; full benefit typically achieved with continued use over weeks."
    },
    {
      "type": "adverse_effects",
      "common": [
        "nausea",
        "insomnia",
        "abnormal dreams",
        "headache",
        "constipation"
      ],
      "less_common": [
        "flatulence",
        "dysgeusia",
        "fatigue"
      ],
      "serious": [
        "neuropsychiatric symptoms",
        "suicidal ideation",
        "myocardial infarction",
        "seizures"
      ]
    },
    {
      "type": "warnings",
      "other": [
        "Monitor for changes in mood, behavior, or suicidal ideation",
        "Use caution in patients with cardiovascular disease",
        "Dose adjust in severe renal impairment"
      ]
    },
    {
      "type": "interactions",
      "items": [
        {
          "with": "Nicotine replacement therapy",
          "risk": "Increased adverse effects such as nausea and headache",
          "action": "Monitor closely"
        },
        {
          "with": "Alcohol",
          "risk": "Increased intoxication or aggressive behavior",
          "action": "Advise caution"
        }
      ]
    },
    {
      "type": "monitoring",
      "items": [
        "Neuropsychiatric symptoms",
        "Mood and behavior",
        "Renal function in impaired patients"
      ]
    },
    {
      "type": "special_populations",
      "pregnancy": "Limited data; use only if benefit outweighs risk",
      "lactation": "Unknown if excreted in human milk; weigh benefits and risks",
      "geriatrics": "No specific dosage adjustments unless renal impairment is present"
    },
    {
      "type": "tapering",
      "text": "No formal tapering required, but gradual dose reduction may be considered if discontinuation symptoms occur."
    },
    {
      "type": "clinical_notes",
      "items": [
        "Behavioral support should accompany pharmacologic treatment for best outcomes",
        "Nausea can be reduced by taking with food and a full glass of water",
        "Some patients may benefit from starting varenicline 1–2 weeks before their planned quit date"
      ]
    },
    {
      "type": "references",
      "items": [
        {
          "label": "Chantix Prescribing Information",
          "url": "https://www.accessdata.fda.gov/"
        },
        {
          "label": "NHS - Varenicline",
          "url": "https://www.nhs.uk/medicines/varenicline/"
        }
      ]
    }
  ],
  "seo": {
    "title": "Varenicline (Chantix) - Uses, Dosage, Side Effects, and Warnings",
    "description": "Varenicline (Chantix) is a smoking cessation aid that reduces cravings and withdrawal symptoms. Learn about dosing, side effects, and precautions."
  }
}
